Skip to content

Advertisement

  • Original article
  • Open Access

Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

†Contributed equally
Chinese Journal of Cancer201736:81

https://doi.org/10.1186/s40880-017-0247-y

©  The Author(s) 2017

  • Received: 23 January 2017
  • Accepted: 19 September 2017
  • Published:

Abstract

Background

The prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking. This study aimed to analyze the clinicopathologic features of and treatment efficacy of commonly used regimens on BRAF-mutated mCRCs.

Methods

We collected and reviewed the medical records of mCRC patients treated at Peking University Cancer Hospital & Institute (Beijing, China) between July 2011 and July 2016. Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing. The details of clinicopathologic characteristics of patients and their responses to FOLFOXIRI regimen or standard therapy were obtained by reviewing the medical records. The progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier analysis and compared using the log-rank test.

Results

Of 1694 patients studied, 75 had BRAF exon 15 mutations. Of these 75 patients, 71 had V600E mutation, 1 had D594G mutation, 2 had K601E mutation, and 1 had a novel T599_V600insAGA alteration. No patients had KRAS or NRAS mutations. Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases. The patients with BRAF K601E- and T599_V600insAGA-mutated tumors had similar clinicopathologic features to those with BRAF V600E-mutated tumors. Patients with the BRAF V600E mutation benefited more from FOLFOXIRI regimen compared with patients who underwent standard therapy (overall response rate 83.3% vs. 14.0%; median PFS 6.4 months vs. 2.8 months, P = 0.220; median OS 11.0 months vs. 6.9 months, P = 0.048).

Conclusions

BRAF V600E mutations were commonly identified in right-sided tumors and showed a high incidence of peritoneal and distant lymph nodes metastases. This subtype of mCRC was characterized by short OS and unique patterns of metastasis. Compared with standard treatment regimens, the FOLFOXIRI regimen had acceptable and manageable toxicities and favorable efficacy on patients with BRAF-mutated mCRC.

Keywords

  • Colorectal cancer
  • BRAF
  • Chemotherapy
  • Prognosis

Background

V-raf murine sarcoma viral oncogene homolog B1 (BRAF), a principal downstream effector of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, is mutated in 5%–10% of colorectal cancer (CRC) cases [1]. It was reported that a thymine to adenine single-base change at position 1799 accounts for 90% of BRAF mutations [2]. This missense mutation, located in exon 15, results in a change at codon 600 that substitutes glutamine for valine (V600E) [2]. BRAF-mutated CRC tends to be mucinous histologically or poorly differentiated [3, 4]. Clinically, BRAF-mutated tumors are primarily located on the right side of the colon and are more prevalent in women and elderly [3, 4]. Lymph nodes and the peritoneum are common metastatic sites [3, 4]. The BRAF V600E mutation is negatively associated with prognosis in patients with metastatic colorectal cancer (mCRC), distinguishing them as a subgroup that obtains modest benefit from standard treatments [5–7].

Although V600E mutation is the most frequently reported BRAF mutation, some CRC have rare BRAF mutations [8]. The studies on BRAF mutations beyond codon 600 in CRC are increasing; although their functional roles and clinical relevance have been discussed [9–11], the clinicopathologic features and prognoses of the CRC patients with rare BRAF mutations are unclear.

Strategies to manage the aggressiveness of BRAF-mutated tumor is challenging. The BRAF V600E mutation has been identified as a biomarker of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies [12]. In addition, results from randomized trials revealed that standard first-line doublets, oxaliplatin + fluorouracil/leucovorin (FOLFOX), oxaliplatin + capecitabine (CapeOX) or irinotecan + fluorouracil/leucovorin (FOLFIRI), plus a monoclonal antibody (cetuximab or bevacizumab) achieved unsatisfactory clinical outcomes for overall survival (OS; 4.3–7.1 months) of BRAF-mutated mCRC patients [13, 14]. Nevertheless, in a phase II trial, upfront use of FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) plus bevacizumab improved clinical outcomes in patients with BRAF-mutated mCRC [15]. The patients’ median progression-free survival (PFS) and median OS were 11.8 and 24.1 months, respectively; overall response rate (ORR) and disease control rate (DCR) were 72% and 88%, respectively [15]. These encouraging results bring hope for the management of this particular subtype of CRC [15].

Subsequently, a recent Tribe 3 randomized trial showed that patients with BRAF-mutated CRC who were treated with FOLFOXIRI plus bevacizumab had longer overall survival than those treated with FOLFIRI plus bevacizumab (19 vs. 10.7 months) [16, 17]. However, bevacizumab is associated with several toxicities [18, 19] and patients with a history of bleeding, thrombotic disorders, hemoptysis, cerebral vascular accident, severe cardiac disease (ischemic or congestive heart failure), or bowel obstruction are not ideal candidates for bevacizumab therapy [20]. Therefore, the intensive FOLFOXIRI regimen appears to be an alternative strategy for treating patients with BRAF-mutated CRC.

In the present study, we retrospectively collected clinical data and tumor samples from patients with BRAF-mutated CRC and analyzed their clinicopathologic characteristics. We also investigated the efficacy of FOLFOXIRI compared with standard doublet-agent treatment (FOLFOX/CapeOX or FOLFIRI) for patients with unresectable BRAF-mutated mCRC.

Patients and methods

Patient population

All patients with mCRC received BRAF (exon 15) testing in Peking University Cancer Hospital & Institute (Beijing, China) between July 2011 and July 2016 (Fig. 1). Patients with BRAF-mutated tumors also received extended RAS (rat sarcoma) testing including Kirsten rat sarcoma viral oncogene homolog (KRAS) exons 2, 3, and 4 and neuroblastoma RAS viral oncogene homolog (NRAS) exons 2, 3, and 4. The patients with insufficient clinical data were excluded. Clinical parameters, including age, gender, histological diagnosis, Eastern Cooperative Oncology Group performance status (ECOG PS), and tumor anatomic location at the initial presentation, were obtained by reviewing the medical records. Tumor sites were classified as the right-sided colon (including the ileocecal junction, cecum, ascending colon, hepatic flexure, and transverse colon), left-sided colon (including the splenic flexure, descending colon, and sigmoid colon), and rectum. All tumors were staged according to the TNM staging system of the American Joint Committee on Cancer (7th version, 2009). All patients provided written informed consent for use of clinical data and samples in medical research. This study was approved by the Ethics Committee of Peking University Cancer Hospital and performed according to Principles of the Declaration of Helsinki.
Fig. 1
Fig. 1

Flow chart of BRAF and RAS testing procedure. BRAF v-raf murine sarcoma viral oncogenes homolog B1; RAS rat sarcoma, NRAS neuroblastoma RAS viral oncogene homolog

Treatment schedules and evaluation

All patients with BRAF-mutated CRC were divided into two groups. Standard therapy group received cytotoxic doublets with or without bevacizumab, and intensive therapy group received a modified FOLFOXIRI regimen. Cytotoxic doublets included CapeOX (oxaliplatin 130 mg/m2 intravenous infusion on day 1, capecitabine 1000 mg/m2 twice daily per os for 14 days every 3 weeks), mFOLFOX (oxaliplatin 85 mg/m2 intravenous infusion on day 1, leucovorin 400 mg/m2 intravenous infusion on day 1, fluorouracil 400 mg/m2 intravenous injection on day 1, then 2400 mg/m2 over 46–48 h continuous infusion every 2 weeks), or FOLFIRI (irinotecan 180 mg/m2 intravenous infusion on day 1, leucovorin 400 mg/m2 intravenous infusion on day 1, fluorouracil 400 mg/m2 intravenous injection day 1, then 2400 mg/m2 over 46–48 h continuous intravenous infusion every 2 weeks) at standard doses [21]. Bevacizumab was given at 5 mg/kg intravenous injection every 2 weeks or 7.5 mg/kg intravenous injection every 3 weeks. Treatment was administered until evidence of progression, unacceptable toxicity, or patient refusal or until completion of 12 cycles. Dosing of FOLFOXIRI was as follows: irinotecan 150 mg/m2 intravenous infusion on day 1, oxaliplatin 85 mg/m2 intravenous infusion on day 1, l-leucovorin (l-LV) 200 mg/m2 intravenous infusion on day 1, and 5-fluorouracil (5-FU) 2800 mg/m2 as a 48-h continuous intravenous infusion starting on day 1, repeated every 2 weeks for a maximum of 9 cycles. In both groups, treatment modifications were permitted according to adverse events and patients’ tolerance. Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0. No prophylactic treatment of neutropenia was recommended. Tumor assessment using computed tomography was performed every 6 weeks or when there was evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

KRAS, NRAS, and BRAF status analysis

Genomic DNA of formalin-fixed, paraffin-embedded (FFPE) sections with ≥ 50% tumor cells (if the content of the tumor cells in sections was lower than 50%, the sections would be microdissected) was extracted using an E.Z.N.A.FFPE DNA Kit (Lot. D3399-01, OMEGA, Norcross, GA, USA) according to the manufacturer’s instructions. All genomic DNA was stored at − 20 °C until use. DNA fragments corresponding to the KRAS/NRAS gene (exon 2/3/4) and the BRAF gene (exon 15) were amplified by PCR using primers shown in Table 1. Each PCR reaction system consisted of 10 × LA PCR buffer II 2 µL, 2.5 mmol/L dNTPs 2 µL, LA Taq 0.1 µL (DRR200A, TaKaRa, Kusatsu, Shiga, Japan), genomic DNA 2 µL, 10 µmol/L forward primer 0.5 µL, and 10 µmol/L reverse primer 0.5 µL in a final volume of 20 µL. The cycling conditions were 95 °C for 5 min; 45 cycles of 95 °C for 30 s, 56 °C for 45 s, and 72 °C for 20 s; and a final extension at 72 °C for 5 min. Details of this type of sequencing are available in the literature [22].
Table 1

PCR primers and fragments for RAS/BRAF testing (KRAS exons 2, 3, and 4; NRAS exons 2, 3, and 4; and BRAF exon 15)

Exon

Primer

Fragment length (bp)

KRAS

 Exon 2

F: 5′-TACTGGTGGAGTATTTGATAG-3′

248

R: 5′-TGGTCCTGCACCAGTAATATG-3′

 Exon 3

F: 5′-GCACTGTAATAATCCAGACTGTG-3′

222

R: 5′-CCCACCTATAATGGTGAATATCTTC-3′

 Exon 4

F: 5′-ATGACAAAAGTTGTGGACAGGTTTTGA-3′

284

R: 5′-ATGATTTTGCAGAAAACAGATCTGTATTTATTTCAG-3′

NRAS

 Exon 2

F: 5′-GAACCAAATGGAAGGTCACACT-3′

243

R: 5′-CCTCACCTCTATGGTGGGATC-3′

 Exon 3

F: 5′-TAGCATTGCATTCCCTGTGGTT-3′

258

R: 5′-CCTGTAGAGGTTAATATCCGCAA-3′

 Exon 4

F: 5′-GCCACTGTACCCAGCCTAATCTTG-3′

287

R: 5′-CACATCTCTACCAGAGTTAATCAACTGATGC-3′

BRAF

 Exon 15

F: 5′-CCTAAACTCTTCATAATGCTTGCTC-3′

211

R: 5′-GTGGAAAAATAGCCTCAATTCTTACC-3′

RAS rat sarcoma, BRAF v-raf murine sarcoma viral oncogene homolog B1, KRAS Kirsten rat sarcoma viral oncogene homolog, NRAS neuroblastoma RAS viral oncogene homolog

Follow-up

The survival data of each patient was obtained by reviewing information from several sources, including clinical records and telephone follow-up. The follow-up was started from each patient’s diagnosis of metastatic disease and carried out every 3 months. The last follow-up was performed in December 2016. Patients whose vital status could not be ascertained were considered to be lost to follow-up. PFS was defined as the time from the date of first treatment to the date of confirmation of disease progression according to RECIST version 1.1, death from any cause, or the last follow-up. OS was defined as the time from the initiation of treatment to the date of death due to any cause or the last follow-up. Patients who were lost during follow-up or those without any event (progression or death) at the last follow-up were censored.

Statistical analysis

Statistical analyses were performed with SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA). Chi square test or Fisher’s exact test was used to compare frequencies between groups. The independent-sample Student’s t test was used to compare differences between groups. The log-rank test was used to compare Kaplan–Meier survival curves. All tests were two-sided, and P < 0.05 were considered statistically significant.

Results

Analysis of KRAS, NRAS, and BRAF status

A total of 1694 patients with mCRC received BRAF (exon 15) testing, and a BRAF mutation was confirmed in 75 patients (Fig. 1). Of these 75 patients, none had RAS mutations; 71 had BRAF V600E mutations, 2 had BRAF K601E mutations that had been previously found in CRC cases [8], 1 had a D594G mutation, and 1 had an AGA insertion between BRAF codons 599 and 600 (T599_V600insAGA alteration) that was not previously registered in the COSMIC database (http://cancer.sanger.ac.uk/cosmic) [8].

Clinicopathologic characteristics of patients with BRAF V600E-mutated mCRC

A total of 63 patients with BRAF V600E mutation who had sufficient clinical data were evaluated (Table 2). At diagnosis, the median age was 54 years (range 24–79 years); 57 (90.5%) patients had an ECOG PS of 0–1, and 6 (9.5%) had an ECOG PS of 2. Of these patients, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 50 (79.4%) had distant lymph node metastases, 29 (46.0%) had liver metastases, 26 (41.3%) had peritoneal metastases, and 12 (19.0%) had lung involvement. Seventeen patients had only one organ involved in metastasis. Twenty-nine patients had poorly differentiated tumors, and 13 had tumors with mucinous or signet-ring histology.
Table 2

Clinicopathologic characteristics of 63 metastatic colorectal cancer (mCRC) patients with BRAF V600E mutation

Characteristic

No. of patients (%)

Gender

 Male

27 (42.9)

 Female

36 (57.1)

ECOG PS

 0

47 (74.6)

 1

10 (15.9)

 2

6 (9.5)

Primary tumor

 Right-sided colon

27 (42.9)

 Left-sided colon

19 (30.2)

 Rectum

17 (26.9)

No. of involved organs

 1

17 (27.0)

 > 1

46 (73.0)

Liver metastasis

 Yes

29 (46.0)

 No

34 (54.0)

Peritoneal metastasis

 Yes

26 (41.3)

 No

37 (58.7)

Distant lymph node metastasis

 Yes

50 (79.4)

 No

13 (20.6)

Lung metastasis

 Yes

12 (19.0)

 No

51 (81.0)

Mucinous or signet-ring cell component

 Yes

13 (20.6)

 No

50 (79.4)

Differentiation (adenocarcinoma)a

Well-moderate

31 (51.7)

Poor

29 (48.3)

ECOG PS Eastern Cooperative Oncology Group performance status

aThree cases were pure signet-ring cell carcinomas or mucinous carcinomas and were excluded here

Treatment effects and toxicities

Among 63 patients with BRAF V600E mutation, 7 did not receive systemic treatment, and only 56 patients were eligible for first-line treatment response assessment. Table 3 shows the clinicopathologic characteristics of the 56 patients in standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI regimen). The median age of standard therapy group was 48 years (range 35–79 years), and the median age of intensive therapy group was 44.5 years (range 34–63 years). For patients in standard therapy group, 7 had a partial response, 30 had stable disease, and 13 progressed under treatment. For intensive therapy group, 5 had partial response, and 1 attained stable disease. Patients in two groups had ORRs of 14.0% (7/50) and 83.3% (5/6), respectively, and DCRs of 74.0% (37/50) and 100% (6/6), respectively.
Table 3

Characteristics of 56 patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI regimen)

Variable

Standard therapy group (n = 50)

Intensive therapy group (n = 6)

Gender

 Male

16 (32.0)

4 (66.7)

 Female

34 (68.0)

2 (33.3)

ECOG performance status

 0

42 (84.0)

5 (83.3)

 1

8 (16.0)

1 (16.7)

 2

0 (0)

0 (0)

Primary tumor

 Right

23 (46.0)

4 (66.7)

 Left

15 (30.0)

2 (33.3)

 Rectum

12 (24.0)

0 (0)

No. of involved organs

 1

13 (26.0)

4 (66.7)

 > 1

37 (74.0)

2 (33.3)

Liver metastases

 Yes

23 (46.0)

6 (100)

 No

27 (54.0)

0 (0)

Peritoneal metastases

 Yes

18 (36.0)

1 (16.7)

 No

32 (64.0)

5 (83.3)

Distant lymph node metastasis

 Yes

38 (76.0)

5 (83.3)

 No

12 (24.0)

1 (16.7)

Lung metastasis

 Yes

9 (18.0)

0 (0)

 No

41 (82.0)

6 (100)

Mucinous or signet-ring cell components

 Yes

9 (18.0)

1 (16.7)

 No

41 (42.0)

5 (83.3)

Differentiation (adenocarcinoma)a

 Well-moderate

27 (54.0)

4 (66.7)

 Poor

20 (40.0)

2 (33.3)

All values are presented as number of patients followed by percentage in parentheses

FOLFOXIRI 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan

aThree cases were pure signet-ring cell carcinomas or mucinous carcinomas and were excluded here

The median follow-up was 11.9 months (95% confidence interval [CI] 7.1–16.2 months). For the 56 patients with BRAF V600E mutation, median PFS was 3.7 months (95% CI 2.1–4.8 months), and median OS was 8.1 months (95% CI 6.2–10.0 months). Median PFS was 2.8 months (95% CI 1.8–3.7 months) for standard therapy group and 6.4 months (95% CI 5.5–7.3 months) for intensive therapy group (P = 0.220). Median OS was 6.9 months (95% CI 5.3–8.5 months) for standard therapy group and 11.0 months (95% CI 6.3–15.7 months) for intensive therapy group (P = 0.048) (Fig. 2).
Fig. 2
Fig. 2

Kaplan–Meier estimates of the survival of standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI [luorouracil, leucovorin, oxaliplatin, and irinotecan] regimen) among mCRC patients with BRAF V600E mutation. mPFS median progression-free survival, mOS median overall survival

For the 56 patients assessable for treatment-associated toxicity, both treatments were relatively well tolerated, and the toxicities were manageable (Table 4); no toxicity-related death occurred in both groups. The most common toxicities were neutropenia (48/56, 85.7%), anemia (34/56, 60.7%), peripheral neurotoxicity (30/56, 53.6%), nausea (27/56, 48.2%), astenia (24/56, 42.8%), thrombocytopenia (20/56, 35.7%), diarrhea (17/56, 30.4%), and vomiting (17/56, 30.4%). The only case of febrile neutropenia occurred in standard therapy group (1/56, 1.8%).
Table 4

The most common toxicities in patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab) and intensive therapy group (treated with modified FOLFOXIRI regimen)

Toxicity (NCI-CTC grade)

Standard therapy group (n = 50)

Intensive therapy group (n = 6)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Thrombocytopenia

18 (36.0)

1 (2.0)

0 (0)

0 (0)

0 (0)

1 (16.7)

0 (0)

0 (0)

Anemia

15 (30.0)

14 (28.0)

3 (6.0)

0 (0)

0 (0)

2 (33.3)

0 (0)

0 (0)

Nausea

15 (30.0)

9 (18.0)

0 (0)

0 (0)

2 (33.3)

1 (16.7)

0 (0)

0 (0)

Peripheral neurotoxicity

13 (26.0)

14 (28.0)

0 (0)

0 (0)

2 (33.3)

1 (16.7)

0 (0)

0 (0)

Astenia

11 (22.0)

11 (22.0)

1 (2.0)

0 (0)

0 (0)

1 (16.7)

0 (0)

0 (0)

Vomiting

10 (20.0)

5 (10.0)

0 (0)

0 (0)

2 (33.3)

0 (0)

0 (0)

0 (0)

Diarrhea

10 (20.0)

4 (8.0)

0 (0)

0 (0)

2 (33.3)

1 (16.7)

0 (0)

0 (0)

Neutropenia

10 (20.0)

13 (26.0)

15 (30.0)

6 (12.0)

0 (0)

2 (33.3)

1 (16.7)

1 (16.7)

Stomatitis

9 (18.0)

5 (10.0)

0 (0)

0 (0)

1 (16.7)

0 (0)

0 (0)

0 (0)

Hypertension

3 (6.0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Hemorrhage

3 (6.0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

All values are presented as number of patients followed by percentage in parentheses

FOLFOXIRI 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, NCI-CTC National Cancer Institute Common Toxicity Criteria

Rare BRAF mutations

Four patients who had right-sided colon tumors with rare BRAF mutations were identified (Table 5). All 4 patients had liver metastases, whereas none of them had lung metastasis. The mutations were BRAF T599_V600insAGA in 1 patient and K601E in 2 patients. These 3 patients had peritoneal and distant lymph node metastasis with mucinous pathology. The fourth patient carried a D594G mutation. None of the 4 mCRC patients harboring rare BRAF mutations reached any therapeutic endpoint yet. At the time of data cutoff on December 2016, patient 4 did not progress after 9 months of treatment.
Table 5

Clinicopathologic characteristics of 4 mCRC patients with rare BRAF mutations

Patient

Gender

BRAF mutation

Age (years)

TNM stage

Differentiation

Mucinous components

Peritoneal metastases

Distant lymph node metastasis

Patient 1

Female

T599_V600insAGA

63

T4aN1cM1

Moderate

No

Yes

Yes

Patient 2

Female

K601E

65

T4N2M1

Moderate

Yes

Yes

Yes

Patient 3

Male

K601E

42

T4N2M1

Poor

Yes

Yes

Yes

Patient 4

Female

D594G

55

T3N2M1

Moderate

No

No

No

All of the 4 patients harboring rare BRAF mutations were identified with right-sided tumors and showed liver metastases

None of the 4 patients showed lung metastases

Discussion

In the present study, BRAF V600E-mutated tumors were more frequently located on the right-sided colon (27/63, 42.9%); nearly half of the patients (26/63, 41.3%) had peritoneal metastasis. mCRC with BRAF V600E mutation was more likely to metastasize to distant lymph nodes (79.4%, 50/63). The median age at diagnosis was 54 years. The median PFS of patients with BRAF V600E mutation was 3.7 months, and median OS was 8.1 months. Thus, this disease was likely to be associated with poor prognosis.

The high occurrence rates of peritoneal and distant lymph node metastases were consistent with the results of previous reports [3, 23, 24]. Tran et al. [23] reported peritoneal metastases in 46% and distant lymph node metastases in 53% of BRAF-mutated mCRCs. Earlier studies identified an association between BRAF mutations in mCRC and older age; the patients with BRAF-mutated mCRC were significantly elder than those with BRAF wild-type tumors (median age 64 years vs. 58 years; P < 0.01) [3]. In contrast, patients with BRAF mutations in our study were younger, with a median age of 54 years. Western patients with BRAF V600E-mutated tumors showed poor outcome with a median survival of 7.2 months [24], which is comparable to the OS of 8.1 months in our study. We confirmed that BRAF V600E-mutated tumors represent a discrete subset of CRC characterized by short OS and unique patterns of metastasis.

Additionally, early work suggested that monotherapy with BRAF inhibitor vemurafenib or another single BRAF inhibitor did not produce the desired antitumoral activity and clinical efficacy [25, 26]. Yaeger et al. [27] reported that median PFS for the patients with BRAF-mutated mCRC who received vemurafenib combined with the anti-EGFR antibody panitumumab was 3.2 months and median OS was 7.6 months. Even a doublet cytotoxic regimen offered modest clinical activity against this highly aggressive and chemoresistant subset of CRC. To date, no effective strategies have been developed to counteract the aggressiveness of BRAF-mutated tumors. Our data suggest that a FOLFOXIR regimen may be effective in such cases. The FOLFOXIRI regimen prolonged PFS and OS, although these outcomes were less favorable than those reported in previous studies [15, 16]. Most of our patients had more than one metastatic site and the sample size was small, which may limit our analysis of survival benefits derived from a triplet-agent treatment. Moreover, the FOLFOXIRI regimen had acceptable and manageable toxicities compared with standard treatment.

In addition, we found K601E mutations in 2 patients diagnosed with advanced-stage CRC and tumors on the right side of the colon who had metastases to distant lymph nodes and the peritoneum. Finally, the BRAF D594G mutation has been previously reported but data suggested that it may not have an association with aggressive tumor phenotypes. Amaki-Takao et al. [10] reported that patients with BRAF D594G-mutated CRCs had similar clinicopathologic features and prognosis as those with BRAF wild-type CRCs. However, only one patient in the present study had BRAF D594G mutation. This patient had stable disease until the last follow-up and no progression occurred within 9 months after first-line treatment. In addition, one novel BRAF T599_V600insAGA alteration was found that has not yet been described previously [8]. The patient was a 63-year-old woman with a primary tumor on the right side of the colon, and she also had lymph node and peritoneal metastases. Based on patient clinical characteristics and the insertion next to the V600 position on the BRAF, we suspect that this newly discovered mutation might have a similar prognostic role as the V600E mutation.

Several patients with BRAF mutation in the present study had longer survival than others, and the data suggest that heterogeneity within BRAF V600E mutations may explain this variation. Barras et al. [28] segregated BRAF mutations into two subtypes according to expression of 476 genes and concluded that the patients with each subtype mutation had different OS and relapse-free survival although not significantly. Thus, the molecular landscapes in 63 patients with BRAF V600E-mutated tumors in the present study would be of interest but are yet to be determined. Also, the effect of a novel BRAF alteration (T599_V600insAGA) on prognosis and in vivo functional testing for this mutation warrants further investigation.

The present study had some limitations. First, there was possible selection bias caused by the retrospective nature of the study and a single cancer. Second, we did not analyze microsatellite stability status and how it influences BRAF status. Third, few patients were treated with the FOLFOXIRI regimen, limiting analysis of survival benefit from this intensive regimen. Even so, this study is a relative large-size report evaluating the BRAF mutation in Chinese patients with mCRC.

In conclusion, BRAF V600E mutations were commonly identified in right-sided mCRCs. High incidences of peritoneal and distant lymph node metastases were observed in mCRC with BRAF V600E mutations. In spite of the poor prognosis, the FOLFOXIRI regimen have shown more favorable efficacy on patients with BRAF-mutated mCRC with acceptable and manageable toxicities compared with standard treatment regimens.

Notes

Declarations

Authors’ contributions

XCW and QW participated in study design and patient selection, performed the PCR studies, performed statistical analysis, and wrote the manuscript. JG and YYL participated in patient selection. JL participated in data analysis. JL and JFG participated in the statistical analysis. LS participated in study design and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Consent for publication

The informed consent of patients was waived because the nature of the study was retrospective and the study did not involve any additional procedures to the standardized clinical protocols. The waiver is approved by the hospital ethics committee.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Peking University Cancer Hospital and performed according to the Principles of the Declaration of Helsinki.

Funding

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China

References

  1. Tol J, Nagtegaal I. Punt C.BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361(1):98–9.View ArticlePubMedGoogle Scholar
  2. Cantwell-Dorris ER, O’Leary JJ, Sheils OM.BRAF V600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385–94.Google Scholar
  3. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120(15):2316–24.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14):6063–9.View ArticlePubMedGoogle Scholar
  5. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931–7.View ArticlePubMedGoogle Scholar
  6. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.View ArticlePubMedGoogle Scholar
  7. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.View ArticlePubMedGoogle Scholar
  8. COSMIC: Catalogue of Somatic Mutation in Cancer. Gene variants for BRAF. http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF Accessed 31 Mar 2017.
  9. Mori Y, Nagasaka T, Mishima H, Umeda Y, Inada R, Kishimoto H, et al. The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma—a report of a case. BMC Med Genet. 2015;16(1):1–4.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Amaki-Takao M, Yamaguchi T, Natsume S, Iijima T, Wakaume R, Takahashi K, et al. Colorectal cancer with BRAF D594G mutation is not associated with microsatellite instability or poor prognosis. Oncology. 2016;91(3):162–70.View ArticlePubMedGoogle Scholar
  11. Cremolini C, Bartolomeo MD, Amatu A, Antoniotti C, Moretto R, Berenato R, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015;26(10):2092–7.View ArticlePubMedGoogle Scholar
  12. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.View ArticlePubMedGoogle Scholar
  13. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101(3):465–72.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–75.View ArticlePubMedGoogle Scholar
  15. Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF, mutant metastatic colorectal cancer. Eur J Cancer. 2014;50(1):57–63.View ArticlePubMedGoogle Scholar
  16. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.View ArticlePubMedGoogle Scholar
  17. Mellas N, Benbrahim Z, El Mesbahi O. Colorectal cancer: new developments after the 2013 ECCO/ESMO congress. Chin J Cancer. 2014;33(4):218–21.PubMedPubMed CentralGoogle Scholar
  18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.View ArticlePubMedGoogle Scholar
  19. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.View ArticlePubMedGoogle Scholar
  20. Caprioni F, Fornarini G. Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol. 2007;3(2):141–8.View ArticlePubMedGoogle Scholar
  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: colon cancer (2017.V1)[EB/OL]. (2016-11-23) [2016-12-22]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  22. Wei Q, Wang X, Gao J, Li J, Li J, Qi C, et al. Clinicopathologic and molecular features of colorectal adenocarcinoma with signet-ring cell component. PLoS ONE. 2016;11(6):e0156659.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011;128(9):2075–84.View ArticlePubMedGoogle Scholar
  25. Mao M, Tian F, Mariadason JT, Tsao CC, Lemos RJ, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19:657–67.View ArticlePubMedGoogle Scholar
  26. Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer. Clin Cancer Res. 2013;19(10):2688–98.View ArticlePubMedGoogle Scholar
  27. Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21(6):1313–20.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res. 2017;23(1):104–15.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement

Cancer Communications

ISSN: 2523-3548

Contact us